Results 131 to 140 of about 31,317 (345)

Effect of adrenergic and cholinergic agents on esophageal bicarbonate secretion in opossums

, 1994
The effects of cholinergic and adrenergic agonists and antagonists on esophageal bicarbonate secretion in the opossum were studied in vivo using a recirculated unbuffered saline solution and pH stat technique.
N. A. Tobey, R. C. Orlando, M. C. Starnes, B. H. Hamilton, V. J. Schreiner   +4 more
core   +1 more source

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, EarlyView.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus, Camille de Almeida, Benoit Bertrand, Julien Castel, Nejmeh Mashhour, Anthony Ansoult, Serge Luquet, Giuseppe Gangarossa   +7 more
wiley   +1 more source

Cholinergic Agonists and Antagonists Have an Effect on the Metabolism of the Beetle Tenebrio Molitor [PDF]

, 2018
Szymon Chowański, Joanna Pacholska‐Bogalska, Grzegorz Rosiński   +2 more
openalex   +1 more source

Muscarinic agonists and antagonists: Effects on the urinary bladder

, 2011
Voiding of the bladder is the result of a parasympathetic muscarinic receptor activation of the detrusor smooth muscle. However, the maintenance of continence and a normal bladder micturition cycle involves a complex interaction of cholinergic ...
Donna J. Sellers, Russ Chess-Williams, Sellers, Donna J., Chess-Williams, Russ   +3 more
core   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Characterization of cholinergic receptors mediating pepsinogen secretion from chief cells

, 1989
By use of a highly enriched preparation of chief cells (greater than 90% pure) prepared from guinea pig stomach, the cholinergic receptors regulating pepsinogen secretion were studied.
R. T. Jensen, V. E. Sutliff, S. Rattan, J. D. Gardner   +3 more
core   +1 more source

Analgesic effects of alpha‐2‐adrenoreceptor agonists in equine medicine: systemic, spinal, and local applications

Equine Veterinary Education, EarlyView.
Summary Alpha‐2‐adrenoreceptor agonists provide analgesia when used as sole agents but can also be used in combination with other drugs for their additive and potentially synergistic effects. Further, because of their effects on blood flow, alpha‐2‐adrenoreceptor agonists act to extend and perhaps intensify the effects of drugs, such as local ...
J. Brandly, J. R. Page, J. A. E. Hubbell, W. W. Muir III, K. Hopster   +4 more
wiley   +1 more source

Radioligandbindungsstudien : Struktur-Wirkungs-Beziehungen von Antagonisten an muskarinischen, serotonergen und histaminergen Rezeptor-Subtypen

, 2008
GPCRs and ligand-gated ion channels mediate a great variety of physiological effects within the human brain and periphery. The search for selective ligands at these target sites as pharmacological tools or new drug candidates is of great interest.
Linder, Matthias
core  

Heterogenous Cholinergic Nicotinic Receptors in the CNS

, 1988
Multiple nicotinic binding sites are found in mammalian brain. Several nicotinic agonists and antagonists have been used to characterize the nicotinic binding sites.
Nilsson, L, Abdu Adem, Luciana Romanelli, Nordberg, A, Lena Nilsson, Adem, A, Xiao Zhang, Zhang, X, Agneta Nordberg, Romanelli, L   +9 more
core   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source